Overall market sentiment has been high on ADMA Biologics Inc (ADMA) stock lately. ADMA receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
ADMA Biologics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ADMA!
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With ADMA Stock Today?
ADMA Biologics Inc (ADMA) stock is down -1.56% while the S&P 500 has gained 0.35% as of 10:25 AM on Friday, Nov 10. ADMA is down -$0.06 from the previous closing price of $3.83 on volume of 370,113 shares. Over the past year the S&P 500 has gained 16.38% while ADMA has gained 52.63%. ADMA lost -$0.20 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for ADMA Biologics Inc click here.
More About ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Click Here to get the full Stock Report for ADMA Biologics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
